On July 5, 2024 IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported that the company plans to issue a pre-market press release and conduct an investor webcast on Monday, July 8, 2024, at 8:00 a.m. EST to provide a clinical data update for the IDE397 Phase 2 monotherapy expansion dose in MTAP-deletion urothelial and non-small cell lung cancer (NSCLC) patients (Press release, Ideaya Biosciences, JUL 5, 2024, View Source [SID1234644688]). IDE397 is a potent and selective potential first-in-class methionine adenosyltransferase 2 alpha (MAT2A) inhibitor in Phase 2 clinical trials for the treatment of methylthioadenosine phosphorylase (MTAP) deletion solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The investor webcast presentation agenda to review the IDE397 clinical data update of the Phase 2 expansion dose results in MTAP-deletion urothelial and NSCLC patients will be the following:
Market introduction: U.S. annual incidence in MTAP-deletion solid tumors
IDE397 preclinical summary in MTAP-deletion
Patient baseline characteristics
Pharmacokinetics and pharmacodynamics
Adverse event profile
Clinical efficacy in 18 evaluable MTAP-deletion urothelial and NSCLC patients by RECIST 1.1
Overall Response Rate (%ORR) and Disease Control Rate (%DCR) analysis
Swimlane plot
ctDNA molecular response analysis
Case reports and CT-scan images
The IDEAYA speakers will include Yujiro S. Hata, Chief Executive Officer, Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, and Michael White, Ph.D., Chief Scientific Officer. The link to the investor webcast will be available on the Investor Relations Events section of the Company’s website at: View Sourceevents" target="_blank" title="View Sourceevents" rel="nofollow">View Source." target="_blank" title="View Sourceevents" target="_blank" title="View Sourceevents" rel="nofollow">View Source." rel="nofollow">View Source Registration is available at View Sourceevents" target="_blank" title="View Sourceevents" rel="nofollow">View Source or View Source in advance of the event.
IDEAYA’s IDE397 investor webcast presentation, as well as an updated corporate presentation, which will incorporate the updated IDE397 clinical data, will be available on the company’s website, at its Investor Relations portal (View Source) at approximately 8:00 am ET on Monday, July 8, 2024.
There is an ongoing Phase 2 expansion of IDE397 monotherapy in MTAP-deletion solid tumors (NCT04794699), and an Amgen-sponsored Phase 1/2 trial of IDE397 and Amgen’s investigational MTA-cooperative protein arginine methytranferase 5 inhibitor AMG 193 combination in MTAP-deletion NSCLC (NCT05975073) for which the companies intend to develop a joint publication strategy in 2024. In addition, IDEAYA has initiated enrollment in a Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of IDE397 in combination with Gilead’s Trop-2 directed anti-body conjugate Trodelvy (NCT04794699). IDEAYA is also advancing multiple preclinical stage MTAP-deletion programs to enable wholly-owned combinations with IDE397, including a program targeting a development candidate nomination in the second half of 2024.